Phase i study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1039-1045

  Tevaarwerk, Amye ^a   Wilding, George ^a   Eickhoff, Jens ^b   Chappell, Rick ^b   Sidor, Carolyn ^c   Arnott, Jamie ^c   Bailey, Howard ^a   Schelman, William ^a   Liu, Glenn ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c ENTREMED INC   (United States)

Author keywords

MKC 1; Novel dose escalation designs; Solid malignancy; TITE CRM

Indexed keywords

ANTINEOPLASTIC AGENT; MKC 1; RO 31 7453; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; OVARY CANCER; PANCREAS CANCER; PAROTID GLAND CARCINOMA; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SARCOMA; SMALL INTESTINE CANCER; SOLID TUMOR; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84864337846     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9629-6     Document Type: Article

References (13)

1. Hanna N, Estes D, Arnott J et al (2009) Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27(suppl):e19005
2. Salazar R, Bissett D, Twelves C et al (2004) A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clin Cancer Res 10:4374-82 (Pubitemid 38878877)
3. Dupont J, Bienvenu B, Aghajanian C et al (2004) Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J Clin Oncol 22:3366-74 (Pubitemid 41103695)
4. Elser C, Hirte H, Kaizer L et al (2009) Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J Clin Oncol 27(suppl):5577
5. Schneider B, Karwal M, Laufman L, et al. (2008) A phase II study of oral MKC-1 for metastatic breast cancer (MBC). J Clin Oncol 26 abstr 1046
6. O'Quigley J, Shen LZ (1996) Continual reassessment method: a likelihood approach. Biometrics 52:673-84 (Pubitemid 26187071)
7. Normolle D, Lawrence T (2006) Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 24:4426-33 (Pubitemid 46630980)
8. Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177-82
9. He W, Liu J, Binkowitz B et al (2006) A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Stat Med 25:2027-42 (Pubitemid 43950277)
10. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205-16
11. Team: RDC: A language and environment for statistical comput-ing. Vienna, Austria., R Foundation for Statistical Computing, 2007
12. Terwogt JM, Schellens JH, Huinink WW et al (1999) Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 25:83-101 (Pubitemid 29353668)
13. Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-61